tiprankstipranks
Cochlear Limited (CH:OC5)
:OC5
Switzerland Market

Cochlear (OC5) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

OC5 Analyst Ratings

Hold
7Ratings
Hold
0 Buy
6 Hold
1 Sell
Based on 7 analysts giving stock ratings to
Cochlear
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

OC5 Stock 12 Month Forecast

Average Price Target

Based on 7 Wall Street analysts offering 12 month price targets for Cochlear in the last 3 months. The average price target is CHF66.83 with a high forecast of CHF75.62 and a low forecast of CHF56.86. The average price target represents a change from the last price of .
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
Highest Price TargetCHF75.62Average Price TargetCHF66.83Lowest Price TargetCHF56.86
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on CH:OC5
Jefferies
Jefferies
CHF73
Hold
Downgraded
07/28/26
Cochlear (CHEOF) was downgraded to a Hold Rating at Jefferies
J.P. Morgan Analyst forecast on CH:OC5
J.P. Morgan
J.P. Morgan
CHF63.11CHF67.89
Hold
Reiterated
07/21/26
Cochlear (CHEOF) Receives a Hold from J.P. Morgan
RBC Capital Analyst forecast on CH:OC5
RBC Capital
RBC Capital
CHF71.07CHF66.52
Hold
Downgraded
07/16/26
RBC Capital downgrades Cochlear (CHEOF) to a Hold
UBS
CHF60.27
Hold
Reiterated
07/15/26
Cochlear (CHEOF) Gets a Hold from UBS
Citi
CHF54.01CHF56.86
Sell
Reiterated
07/13/26
Citi Remains a Sell on Cochlear (CHEOF)
Ord Minnett Analyst forecast on CH:OC5
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
CHF87.56CHF75.62
Hold
Reiterated
07/02/26
Ord Minnett Reaffirms Their Hold Rating on Cochlear (CHEOF)
Macquarie Analyst forecast on CH:OC5
Unknown Analyst
Macquarie
Not Ranked
Macquarie
CHF65.39CHF67.66
Hold
Reiterated
06/30/26
Macquarie Remains a Hold on Cochlear (CHEOF)
Canaccord Genuity Analyst forecast on CH:OC5
Canaccord Genuity
Canaccord Genuity
CHF167.73CHF68.23
Buy
Reiterated
04/29/26
Canaccord Genuity Reaffirms Their Buy Rating on Cochlear (CHEOF)
Morgan Stanley Analyst forecast on CH:OC5
Morgan Stanley
Morgan Stanley
CHF110.3CHF67.66
Hold
Upgraded
04/23/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cochlear (Other OTC: CHEOF), CervoMed (NASDAQ: CRVO) and Community Health (NYSE: CYH)
Morgans
CHF122.2CHF60.93
Hold
Reiterated
04/23/26
Cochlear (CHEOF) Gets a Hold from Morgans
Jarden
CHF127.36CHF96.09
Hold
Reiterated
04/22/26
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW), West Pharmaceutical Services (NYSE: WST) and Cochlear (Other OTC: CHEOF)
Goldman Sachs Analyst forecast on CH:OC5
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
CHF139.24CHF122.7
Hold
Reiterated
03/13/26
Goldman Sachs Keeps Their Hold Rating on Cochlear (CHEOF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on CH:OC5
Jefferies
Jefferies
CHF73
Hold
Downgraded
07/28/26
Cochlear (CHEOF) was downgraded to a Hold Rating at Jefferies
J.P. Morgan Analyst forecast on CH:OC5
J.P. Morgan
J.P. Morgan
CHF63.11CHF67.89
Hold
Reiterated
07/21/26
Cochlear (CHEOF) Receives a Hold from J.P. Morgan
RBC Capital Analyst forecast on CH:OC5
RBC Capital
RBC Capital
CHF71.07CHF66.52
Hold
Downgraded
07/16/26
RBC Capital downgrades Cochlear (CHEOF) to a Hold
UBS
CHF60.27
Hold
Reiterated
07/15/26
Cochlear (CHEOF) Gets a Hold from UBS
Citi
CHF54.01CHF56.86
Sell
Reiterated
07/13/26
Citi Remains a Sell on Cochlear (CHEOF)
Ord Minnett Analyst forecast on CH:OC5
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
CHF87.56CHF75.62
Hold
Reiterated
07/02/26
Ord Minnett Reaffirms Their Hold Rating on Cochlear (CHEOF)
Macquarie Analyst forecast on CH:OC5
Unknown Analyst
Macquarie
Not Ranked
Macquarie
CHF65.39CHF67.66
Hold
Reiterated
06/30/26
Macquarie Remains a Hold on Cochlear (CHEOF)
Canaccord Genuity Analyst forecast on CH:OC5
Canaccord Genuity
Canaccord Genuity
CHF167.73CHF68.23
Buy
Reiterated
04/29/26
Canaccord Genuity Reaffirms Their Buy Rating on Cochlear (CHEOF)
Morgan Stanley Analyst forecast on CH:OC5
Morgan Stanley
Morgan Stanley
CHF110.3CHF67.66
Hold
Upgraded
04/23/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cochlear (Other OTC: CHEOF), CervoMed (NASDAQ: CRVO) and Community Health (NYSE: CYH)
Morgans
CHF122.2CHF60.93
Hold
Reiterated
04/23/26
Cochlear (CHEOF) Gets a Hold from Morgans
Jarden
CHF127.36CHF96.09
Hold
Reiterated
04/22/26
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW), West Pharmaceutical Services (NYSE: WST) and Cochlear (Other OTC: CHEOF)
Goldman Sachs Analyst forecast on CH:OC5
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
CHF139.24CHF122.7
Hold
Reiterated
03/13/26
Goldman Sachs Keeps Their Hold Rating on Cochlear (CHEOF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
ZURAZura Bio
TNYATenaya Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cochlear

3 Months
Shane StoreyCanaccord Genuity
Success Rate
5/9 ratings generated profit
56%
Average Return
-3.96%
Copying Shane Storey's trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of -3.96% per trade.
1 Year
Shane StoreyCanaccord Genuity
Success Rate
2/9 ratings generated profit
22%
Average Return
-21.12%
Copying Shane Storey's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -21.12% per trade.
2 Years
Shane StoreyCanaccord Genuity
Success Rate
2/9 ratings generated profit
22%
Average Return
-23.28%
Copying Shane Storey's trades and holding each position for 2 Years would result in 22.22% of your transactions generating a profit, with an average return of -23.28% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OC5 Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
3
5
5
2
0
Buy
6
8
3
3
0
Hold
10
14
9
10
9
Sell
3
3
2
1
1
Strong Sell
0
0
0
0
0
total
22
30
19
16
10
In the current month, OC5 has received 0 Buy Ratings, 9 Hold Ratings, and 1 Sell Ratings. OC5 average Analyst price target in the past 3 months is 66.83.
Each month's total comprises the sum of three months' worth of ratings.

OC5 Financial Forecast

OC5 Earnings Forecast

Next quarter’s earnings estimate for OC5 is CHF0.96 with a range of CHF0.69 to CHF1.08. The previous quarter’s EPS was CHF1.70. OC5 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.00% of the time in the same period. In the last calendar year OC5 has Performed in-line its overall industry.
Next quarter’s earnings estimate for OC5 is CHF0.96 with a range of CHF0.69 to CHF1.08. The previous quarter’s EPS was CHF1.70. OC5 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.00% of the time in the same period. In the last calendar year OC5 has Performed in-line its overall industry.

OC5 Sales Forecast

Next quarter’s sales forecast for OC5 is CHF668.34M with a range of CHF643.30M to CHF699.71M. The previous quarter’s sales results were CHF670.08M. OC5 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 58.90% of the time in the same period. In the last calendar year OC5 has Performed in-line its overall industry.
Next quarter’s sales forecast for OC5 is CHF668.34M with a range of CHF643.30M to CHF699.71M. The previous quarter’s sales results were CHF670.08M. OC5 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 58.90% of the time in the same period. In the last calendar year OC5 has Performed in-line its overall industry.

OC5 Stock Forecast FAQ

What is CH:OC5’s average 12-month price target, according to analysts?
Based on analyst ratings, Cochlear Limited’s 12-month average price target is 66.83.
    What is CH:OC5’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:OC5, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Cochlear Limited a Buy, Sell or Hold?
        Cochlear Limited has a consensus rating of Hold, which is based on 0 buy ratings, 6 hold ratings and 1 sell ratings.
          What is Cochlear Limited’s share price target?
          The average share price target for Cochlear Limited is 66.83. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF75.62 ,and the lowest forecast is CHF56.86. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Cochlear Limited?
            Cochlear Limited’s analyst rating consensus is a Hold. This is based on the ratings of 7 Wall Streets Analysts.
              How can I buy shares of Cochlear Limited?
              To buy shares of CH:OC5, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.